Actos & Bladder Cancer

In 2014, a team of researchers led by SM Jin published the results of a study that aimed to determined if low doses of pioglitazone (Actos) also raised the risk for bladder cancer among diabetic patients.  It has already been demonstrated by many other studies that long-term and high-dose Actos therapy dramatically raises the risk